Product Search for novus: Novus Biologicals

Novus Biologicals products are now on bio-techne.com

Sort By:

Products (1)

page of 1

1 Results for "novus"

NBP1-60046

MUC1 Antibody - BSA Free

(8 Publications)

0.1 mg

NBP1-60046

Knockout Validated: MUC1 Antibody - BSA Free [NBP1-60046] - MUC1 Antibody [NBP1-60046] - C57BL/6 Muc1 KO mice and WT mice were undergoing intranasal instillation of 75 ug of lipopolysaccharide (LPS) at day 1. Between days 2 and 3, animals were exposed to cigarette smoke (or control air) of 6 cigarettes followed by 8 cigarettes (or control air) at days 4 and 5, and 10 cigarettes (or control air) at day 6. Vehicle or dexamethasone at 3 mg/kg/day and 10 mg/kg/day was administered orally once a day between day 1 and 6. Animals were sacrificed at day 6 and lungs were homogenized to analyze protein expression of Muc1 cytoplasmic tail (CT). Protein expression was normalized to B-actin. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0927-4) licensed under a CC-BY license.

<b>Genetic Strategies Validation. </b>Knockout Validated: MUC1 Antibody [NBP1-60046] - Dexamethasone induces Muc1-CT nuclear translocation and co-localization with GRa in bronchial epithelium of WT mice but not in MUC1 KO mice. C57BL/6 Muc1 KO mice and WT mice were undergoing dexamethasone 10 mg/kg/day (orally) for 6 days. Animals were sacrificed at day 6 and lungs were fixed in paraformaldehyde (4%) for 48 h and embedded. Lung slices were immunostained with MUC1-cytoplasmic tail (CT) (red) and glucocorticoid receptor alpha (GRa) antibodies (green) with rhodamine/fluorescein secondary antibodies. DAPI was used to mark cell nucleus. Representative con-focal images are showed. Scale bar: 5 um. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0927-4) licensed under a CC-BY license.

Western Blot: MUC-1 Antibody [NBP1-60046] - Total protein from mouse 3T3 cells and human HeLa cells, stomach and colon was separated on a 4-15% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-MUC-1 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: MUC1 Antibody [NBP1-60046] - Tested in HeLa cells at a 1:50 dilution against DyLight 488 (Green). Cells were counterstained for alpha-tubulin against DyLight 550 (Red) and mounted in DAPI fluoromount (Blue).

Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Human kidney lysate tissue at an antibody concentration of 4-8ug/ml.

Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Pig stomach.

Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Pig stomach.

Immunohistochemistry-Paraffin: MUC1 Antibody [NBP1-60046] - Human stomach.

MUC1 binds RIPK1 to mediate the RIPK1/RIPK3 pathway. (c,d) Normal 16HBE cells were treated with TNF-alpha for 24 hr, and the interaction between MUC1-CT and RIPK1/RIPK3 were confirmed by immunoprecipitation. Data are expressed as means +/- SD and were analyzed by one-way analysis of variance, *p < 0.05. NC group (transfected with NC siRNA); MUC1-siRNA group (transfected with MUC1-siRNA). 16HBE: human bronchial epithelial; IB: immunoblotting; IP: immunoprecipitation; RIPK1: receptor-interacting protein kinase-1; RIPK3: receptor-interacting protein kinase-3; NC: negative control; siRNA: small interfering RNA; TNF-alpha: tumor necrosis factor-alpha Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30666647), licensed under a CC-BY licence.

$PARKIN down regulation and impairment of mitophagy in DS fibroblasts.a, b Whole-cell extracts from 2 N and DS cells were analyzed by western blot for PARKIN and PINK1. Each quantitative data was normalized with ACTIN. (n ≥ 3). c 2 N and DS cells were assessed for PARKIN and PINK1 mRNA by quantitative real-time PCR. mRNA levels were normalized to ACTIN mRNA, used as internal control. Data display the fold-changes of PARKIN, PINK1 and SQSTM1 (p62) mRNAs relative to control cells (n ≥ 3). d Mitochondrion/cytosol fractionation was performed to assay the presence of PARKIN and LC3-II within the mitochondrial fraction. VDAC1 and COXIV were used as markers of purity for mitochondrial fraction. beta III-TUBULIN was used as a marker of the cytosolic fraction. e Quantitative data of LC3-II in the mitochondrial fraction, normalized with VDAC1 (n = 5). f Mitochondrial fractionation was performed to assess the accumulation of p62, LC3-II, NDP52 and OPTINEURIN (OPTN) within the mitochondria in untreated and treated fibroblasts with a lysosomal-inhibiting agent, Bafilomycin A (Bafil., 10 nM) for 6 h. Each protein was normalized with VDAC1 with quantitation in (g). (n ≥ 3) h 2 N and DS cells were treated with Concanamycin A (ConA, 50 nM) for 2 h to block lysosome function. The cells were fixed and immunostained for LC3 and TOM20 in order to evaluate mitophagy. White arrows point to the co-localization of puncta into the high magnification image of the boxed area. Scale bar 10 μm. The graph shows the percentage of LC3/TOM20 colocalization calculated by JACoP plugin of ImageJ. Quantitation based on a minimum of 50 cells per conditions from three independent experiments. i GSEA analysis of transcriptomic changes comparing DS fibroblasts to 2 N fibroblasts, using a list of transcriptional factors that have been described to be involved in mitophagy46,47 (for list of genes, see Supp. Table 1). As described in Fig. 1d, the vertical bars represent genes ranked horizontally by moderated t-statistics; Pink, blue and grey shaded rectangles upregulated, downregulated and genes with no change respectively. The plot shows significant downregulation of TFs involved in mitophagy in DS compared to 2 N fibroblasts (p < 0.001; FDR < 0.001). j Volcano plots for whole transcriptomes of differentially expressed genes between DS and 2 N fibroblasts, with TFs involved in mitophagy, used in (I) for GSEA analysis highlighted with labels. Statistical analysis was performed using Student’s T-test or one-way ANOVA with Tukey’s multiple comparisons test. (**p < 0.01; ***p < 0.001). Immunoblots reported are from one representative experiment Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31332166), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

HIF-1 alpha -mediated repression of ENT1 expression in Caki-1 cells under hypoxia. Comparison of HIF-1 alpha and HIF-2 alpha protein expression in human matched renal normal-tumor samples (n=11) (A) and 3 RCC cell lines (786-O, 769-P, Caki-1) under normoxia or hypoxia for 6 h (B). (C) Schematic diagram of two hypoxia response elements (HRE) in the promoter of ENT1. (D) CHIP-qPCR analysis of HIF-1 alpha at the promoter of ENT1 in Caki-1 cells, exposed under normoxia or hypoxia for 48 h. Two different HIF-1 alpha antibodies (610958, BD Biosciences; NB100-105, Novus) were used to pull down HIF-1 alpha . The protein expression level of HIF-1 alpha (E) and mRNA expression level of SLC29A1 (F) in Caki-1 under normoxia or hypoxia and HIF-1 alpha knockout-Caki-1 cells. (G) The expression level of ARNT1 (HIF-1 beta ) was detected in Caki-1, transfected with ARNT1 specific siRNAs or NC. Student's t test (two-tailed) was used. (H, I) The expression level of ENT1 in Caki-1, transfected with ARNT1 specific siRNAs or NC, under normoxia or hypoxia. Oneway-ANOVA analysis was used. The results are expressed as mean ± SEM (n=3). ***P<0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32206108), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Experimental setup and the effect of PHD3 silencing on 786-O proteome. a siRNA-mediated silencing of PHD3 protein level in 786-O ccRCC cell line using two individual siRNA sequences in normoxic and in hypoxic (1% O2) condition. Quantification of three biological replicates, mean ± SEM, fold change to control (Scr). Asterisk indicates a statistically significant difference (*p < 0.05, **p < 0.01). b siRNA-mediated silencing of PHD3 mRNA expression, quantification of three individual experiments. Mean ± SEM, fold change to Scr (***p < 0.001). c Flow chart of the experimental procedure. 786-O cells were transfected with siPHD3#1 or with a non-targeting control siRNA (Scr) for 24 h followed by a hypoxic (1% O2) or normoxic (21% O2) exposure. Three independent experiments were performed; proteins were extracted, followed by in-gel digestion with trypsin. Purified peptides were ran through mass spectrometer. Protein identification was done with Mascot database search. Protein quantification was carried out with Progenesis QI, followed by testing the differential expression between sample groups using peptide-level expression change averaging (PECA). d Western blot validations of selected proteins in 786-O and RCC4 cell lines with two individual siRNA sequences targeting PHD3, representative analyses are shown Image collected and cropped by CiteAb from the following open publication (//cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-017-0167-y), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Photomicrographs of immunostaining for osteocalcin and osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) and the investigated treatment (rows). Areas that stained positive for osteocalcin and osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected and cropped by CiteAb from the following open publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Po, Bv, Eq, Gp, Gt, Rb, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Bv, Eq, Gp, Gt, Rb, Pm

Applications:

, , , ,

Applications: , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP1-60046AF350
Alexa Fluor 405	NBP1-60046AF405
Alexa Fluor 488	NBP1-60046AF488
Alexa Fluor 532	NBP1-60046AF532
Alexa Fluor 594	NBP1-60046AF594
Alexa Fluor 647	NBP1-60046AF647
Alexa Fluor 700	NBP1-60046AF700
Alexa Fluor 750	NBP1-60046AF750
Biotin	NBP1-60046B
DyLight 350	NBP1-60046UV
DyLight 405	NBP1-60046V
DyLight 488	NBP1-60046G
DyLight 550	NBP1-60046R
DyLight 594	NBP1-60046DL594
DyLight 650	NBP1-60046C
DyLight 680	NBP1-60046FR
DyLight 755	NBP1-60046IR
FITC	NBP1-60046F
HRP	NBP1-60046H
Janelia Fluor 549	NBP1-60046JF549
Janelia Fluor 646	NBP1-60046JF646
mFluor Violet 450 SE	NBP1-60046MFV450
mFluor Violet 500 SE	NBP1-60046MFV500
mFluor Violet 610 SE	NBP1-60046MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP1-60046SS

compare

(select up to 3 products from this page to compare)

page of 1

Popular Products	Company Information	Support	Stay Connected
Antibodies Secondary Antibodies Isotype Controls Proteins and Peptides ELISA Kits Sample Size New Products	About Us Careers Novus Guarantee Contact Us Our Team	Technical Support FAQs Help Finding Antibodies Protocols

Visit our other sites

©2024 Novus Biologicals, All Rights Reserved.